Evidence map›Paper›PMID 32436109›Full record

SynthesisCurrent rheumatology reports2020

New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis.

Virginie Dufrost, Luc Darnige, Tatiana Reshetnyak, Maria Vorobyeva, Xin Jiang, Xin-Xin Yan, Grigorios Gerotziafas, Zhi-Cheng Jing, Ismaël Elalamy, Denis Wahl and 1 more

Registry-linked trialAbstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Current rheumatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06884384 (Direct Oral Anticoagulants Versus Warfarin in Patients With Non-high-risk Antiphospholipid Syndrome), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06884384 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Direct Oral Anticoagulants Versus Warfarin in Patients With Non-high-risk Antiphospholipid Syndrome : Prospective Cohort Study

TypeobservationalSponsorCentral Hospital, Nancy, FranceRan2025 to 2031Enrolled310ConditionsAntiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding EventsArmsAdditional blood collection during routine blood sampling at the inclusion (33.9 ml) and at the thrombotic recurrence (between 3.5 and 5 ml), Completion of a questionnaire on compliance with anticoagulant treatment, Completion of a questionnaire on satisfaction with treatment anticoagulant
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Thrombotic Antiphospholipid Syndrome: Recurrent Thromboses.Doklady. Biochemistry and biophysics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 3 countries.

Virginie DufrostInserm UMR_S 1116 and CHRU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Université de Lorraine, Nancy, France.
Luc DarnigeInserm UMR-S 1140, Service d'Hématologie Biologique, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France.
Tatiana ReshetnyakLaboratory of Vascular Rheumatology, V.A. Nasonova Research Institute of Rheumatology, 115522, Kashirskoye Shosse 34a, Moscow, Russia.
Maria VorobyevaLaboratory of Vascular Rheumatology, V.A. Nasonova Research Institute of Rheumatology, 115522, Kashirskoye Shosse 34a, Moscow, Russia.
Xin JiangDepartment of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xin-Xin YanThe Key Laboratory of Pulmonary Vascular Medicine, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
Grigorios GerotziafasCancer Biology and Therapeutics, Centre de Recherche Saint-Antoine, Institut National de la Santé et de la Recherche Médicale (INSERM) U938 and Institut Universitaire de Cancérologie, Faculté de Médecine, Sorbonne Université, Paris, France.
Zhi-Cheng JingDepartment of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ismaël ElalamyCancer Biology and Therapeutics, Centre de Recherche Saint-Antoine, Institut National de la Santé et de la Recherche Médicale (INSERM) U938 and Institut Universitaire de Cancérologie, Faculté de Médecine, Sorbonne Université, Paris, France.
Denis WahlInserm UMR_S 1116 and CHRU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Université de Lorraine, Nancy, France.
Stéphane ZuilyInserm UMR_S 1116 and CHRU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Université de Lorraine, Nancy, France. s.zuily@chru-nancy.fr.
Inserm · FRVA Nasonova Scientific Research Institute of Rheumatology · RUAssistance Publique – Hôpitaux de Paris · FRChinese Academy of Medical Sciences & Peking Union Medical College · CNFu Wai Hospital · CNHôpital Européen Georges-Pompidou · FRPeking Union Medical College Hospital · CNSorbonne Université · FRUniversité de Lorraine · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe efficacy of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS) is discussed. Results from randomized controlled trials are available. It has been stated that a history of arterial thrombosis and triple positivity was associated with a higher risk of thrombosis in APS patients treated with DOACs. However, their efficacy in non-high-risk APS patients with isolated venous manifestations is unsolved. Therefore, we performed a sub-group analysis of a previously published meta-analysis after the exclusion of patients with triple positivity and those with history of arterial or small vessel thrombosis. RECENT

findingsWe identified 290 APS patients with previous isolated venous event treated with DOACs; among them, 25 (8.6%) patients experienced a recurrent thrombosis in comparison to 16% in the original cohort. We found that the rate of recurrent thrombosis is lower in APS patients with isolated venous manifestations than in overall APS patients including high-risk patients. Research about DOAC use in non-high-risk APS patients needs to be continued.

Indexed as

AnticoagulantsAntiphospholipid SyndromeThrombosisHumansAnticoagulantsAntiphospholipid antibodiesAntiphospholipid syndromeDabigatranDirect oral anticoagulantsRivaroxabanThrombosis recurrence

Identifiers

PMID32436109
OpenAlexW3027952476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.